Daclatasvir Dihydrochloride
Description
Daclatasvir dihydrochloride (BMS-790052 dihydrochloride) is a potent and orally active HCV NS5A protein inhibitor with EC50s range of 9-146 pM for multiple HCV replicon genotypes. Daclatasvir dihydrochloride is also a organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC50s of 1.5 µM and 3.27 µM, respectively.
IC50 & Target
EC50: 50 pM (HCV replicon genotype 1a), 9 pM (HCV replicon genotype 1b), 71 pM (HCV replicon genotype 2a), 146 pM (HCV replicon genotype 3a), 12 pM (HCV replicon genotype 4a) and 33 pM (HCV replicon genotype 5a)[1]
Kd: 8 nM (NS5A33-202) and 210 nM (NS5A26-202)[2]
IC50: 1.5 µM (OATP1B) and 3.27 µM (OATP1B3)[3]
In Vitro
Daclatasvir (BMS-790052) demonstrates potent inhibitory activity towards all genotypes tested, with EC50 values ranging from 9 pM to 146 pM. Daclatasvir inhibits HCV replicon genotype 1a, 1b, 2a, 3a, 4a and 5a with EC50 values of 50 pM, 9 pM, 71 pM, 146 pM, 12 pM and 33 pM, respectively. Daclatasvir is a potent inhibitor of the JFH-1 genotype 2a infectious virus that replicates in cell culture (EC50=28 pM)[1]. Daclatasvir (BMS-790052) binds tightly to NS5A33-202 and NS5A26-202 with Kds of 8 nM and 210 nM, respectively[2].
Storage
Powder |
-20°C |
3 years |
4°C |
2 years | |
In solvent |
-80°C |
6 months |
-20°C |
1 month |
Clinical Trial
NCT Number | Sponsor | Condition | Start Date |
Phase |
NCT03369327 | Tehran University of Medical Sciences|RojanPharma Pharmaceutical Company | Hepatitis C Virus Infection, Response to Therapy of|Human Immunodeficiency Virus | January 1, 2017 |
Phase 3 |
NCT03485846 | R-Pharm|Almedis | Chronic Hepatitis C Genotype 1b | November 27, 2017 |
Phase 2 |
NCT01016912 | Bristol-Myers Squibb | Hepatitis C Infection | December 2009 |
Phase 2 |
NCT01629732 | Bristol-Myers Squibb | Hepatitis C Virus | March 2013 |
Phase 2 |
NCT01497834 | Bristol-Myers Squibb | Hepatitis C | January 2012 |
Phase 3 |
NCT01973049 | Bristol-Myers Squibb | Hepatitis C | December 2013 |
Phase 3 |
NCT00663208 | Bristol-Myers Squibb | Chronic Hepatitis C | May 2008 |
Phase 2 |
NCT02576314 | Humanity and Health Research Centre|Beijing 302 Hospital | Chronic Hepatitis C Infection | May 2015 |
Phase 3 |
NCT02756936 | Genuine Research Center, Egypt|Zeta Pharma Pharmaceutical Industries | Healthy | February 2016 |
Phase 1 |
NCT02771405 | National Hepatology & Tropical Medicine Research Institute|Cairo University | Hepatitis C, Chronic|Hepatocellular Carcinoma | March 2016 |
Phase 3 |
NCT03706898 | Viriom | HIV-1-infection|Hepatic Impairment | October 1, 2018 |
Phase 1 |
NCT02319031 | Bristol-Myers Squibb | Hepatitis C | February 2015 |
Phase 3 |
NCT02124044 | National Institutes of Health Clinical Center (CC)|National Institute of Allergy and Infectious Diseases (NIAID)|Bristol-Myers Squibb | HIV-HCV | February 2014 |
Phase 2 |
NCT02551861 | Bristol-Myers Squibb | Hepatitis C | December 2015 |
Phase 2 |
NCT00859053 | Bristol-Myers Squibb | Hepatic Insufficiency | March 2009 |
Phase 1 |
NCT01257204 | Bristol-Myers Squibb | Hepatitis C Virus | December 2010 |
Phase 2 |
NCT03063879 | Tehran University of Medical Sciences|Ahvaz Jundishapur University of Medical Sciences|Shiraz University of Medical Sciences|Hamadan University of Medical Science | Hepatitis C, Chronic|Chronic Renal Failure | April 1, 2017 |
Phase 4 |
NCT01017575 | Bristol-Myers Squibb | Hepatitis C Infection | December 2009 |
Phase 2 |
NCT02865369 | Sang Gyune Kim|Seoul National University Boramae Hospital|Severance Hospital|Inha University Hospital|Korea University|Gachon University Gil Medical Center|Hanyang University Seoul Hospital|Ewha Womans University Mokdong Hospital|Bristol-Myers Squibb|Soonchunhyang University Hospital | Chronic Hepatitis C | September 2016 |
|
NCT04070235 | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Hepatitis C, Chronic | March 29, 2019 |
Phase 2|Phase 3 |
NCT03487848 | Bristol-Myers Squibb | Hepatitis C|Chronic Hepatitis | May 18, 2018 |
Phase 2 |
NCT00904059 | Bristol-Myers Squibb | Hepatitis C | May 2009 |
Phase 1 |
NCT02107365 | French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Bristol-Myers Squibb | Hepatitis C Virus Genotype 4 Infection | November 2013 |
Phase 2 |
NCT02397395 | Janssen R&D Ireland | Renal Impairment|End-stage Renal Disease | May 2015 |
Phase 2 |
NCT03169348 | Assiut University | Hepatitis C | November 1, 2017 |
Not Applicable |
NCT02323594 | Bristol-Myers Squibb | Hepatitis C Infection | December 2014 |
Phase 1 |
NCT03537196 | French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS) | Hepatitis C|Drug Use|Viral Hepatitis C | November 13, 2018 |
Phase 4 |
NCT02103569 | Bristol-Myers Squibb | Hepatitis C | April 2014 |
Phase 1 |
NCT02772744 | Zagazig University|Cairo University | Hepatitis C | November 1, 2017 |
|
NCT01718158 | Bristol-Myers Squibb | Hepatitis C | January 2013 |
Phase 3 |
NCT02496078 | Bristol-Myers Squibb | Hepatitis C | August 2015 |
Phase 3 |
NCT01425970 | Bristol-Myers Squibb | Hepatitis C | May 2012 |
Phase 2 |
NCT01471574 | Bristol-Myers Squibb | Hepatitis C, Genotype 1 | December 2011 |
Phase 3 |
NCT01573351 | Bristol-Myers Squibb | Hepatitis C Virus | May 2012 |
Phase 3 |
NCT01938625 | Janssen R&D Ireland | Hepatitis C, Chronic | December 12, 2013 |
Phase 2 |
NCT01492426 | Bristol-Myers Squibb | Hepatitis C | January 2012 |
Phase 3 |
NCT03480932 | Johns Hopkins Bloomberg School of Public Health|National Institute on Drug Abuse (NIDA)|YR Gaitonde Centre for AIDS Research and Education | Hepatitis C, Chronic | February 2, 2018 |
Phase 2|Phase 3 |
NCT03163849 | Assiut University | Chronic Hepatitis c | September 1, 2019 |
Phase 3 |
NCT01581203 | Bristol-Myers Squibb | Hepatitis C Virus | May 2012 |
Phase 3 |
NCT01492504 | Bristol-Myers Squibb | Hepatitis C | February 7, 2012 |
|
NCT03686722 | Mohamed Raslan|Ain Shams University|Drug Research Centre, Cairo, Egypt | Diabetes Mellitus, Type 2|Hepatitis C|Drug Interactions | September 9, 2017 |
Phase 1 |
NCT02262728 | Janssen Research & Development, LLC | Hepatitis C, Chronic | September 30, 2014 |
Phase 2 |
NCT02349048 | Janssen Research & Development, LLC | Hepatitis C Virus | January 2015 |
Phase 2 |
NCT03882307 | Assiut University | Hepatitis C, Chronic | May 2020 |
Early Phase 1 |
NCT02758509 | Parc de Salut Mar | Chronic Hepatitis C|Cirrhosis | January 1, 2010 |
|
NCT01795911 | Bristol-Myers Squibb | Hepatitis C | March 2013 |
Phase 2 |
NCT03549832 | Assiut University|Sohag University|South Valley University | HCV Coinfection | January 1, 2018 |
Not Applicable |
NCT02161939 | Bristol-Myers Squibb | Chronic Hepatitis C |
|
|
NCT01309932 | Bristol-Myers Squibb | Hepatitis C | March 2011 |
Phase 2 |
NCT01995266 | Bristol-Myers Squibb | Hepatitis C | February 28, 2014 |
Phase 3 |
NCT02640157 | AbbVie | Chronic Hepatitis C|Hepatitis C Virus|Genotype 3 Hepatitis C Virus | December 2015 |
Phase 3 |
NCT02032875 | Bristol-Myers Squibb | Hepatitis C | March 2014 |
Phase 3 |
NCT02624063 | Federal University of São Paulo | Hepatitis C, Chronic | December 2015 |
Phase 4 |
NCT00546715 | Bristol-Myers Squibb | Chronic Hepatitis C | November 2007 |
Phase 1|Phase 2 |
NCT01718145 | Bristol-Myers Squibb | Hepatitis C Virus Infection | November 2012 |
Phase 3 |
NCT01616524 | Bristol-Myers Squibb | Hepatitis C Virus (HCV) | July 2012 |
Phase 3 |
NCT02032901 | Bristol-Myers Squibb | Hepatitis C | January 2014 |
Phase 3 |
NCT03540212 | Ain Shams University | Chronic HCV Infection | December 10, 2017 |
Phase 2|Phase 3 |
NCT02097966 | Bristol-Myers Squibb | Chronic Hepatitis C |
|
|
NCT02596880 | Tehran University of Medical Sciences | Hepatitis C|Cirrhosis | September 2015 |
Phase 3 |
NCT04019717 | Atea Pharmaceuticals, Inc. | Hepatitis C|Hepatitis C, Chronic|Chronic Hepatitis C|Hepatitis C Virus Infection|HCV Infection | June 20, 2019 |
Phase 2 |
NCT02992457 | Tanta University | Hepatitis C | January 2015 |
Phase 4 |
NCT03547895 | Zagazig University | Decompensated Cirrhosis | June 1, 2015 |
Not Applicable |
NCT03004625 | Kaohsiung Medical University Chung-Ho Memorial Hospital|Chang Gung Memorial Hospital|National Taiwan University Hospital|Taipei Veterans General Hospital, Taiwan|China Medical University Hospital|National Cheng-Kung University Hospital | Hepatitis C | November 2016 |
Phase 3 |
NCT01051414 | Bristol-Myers Squibb | Hepatitis C Infection | April 2010 |
Phase 2 |
NCT02309450 | French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Bristol-Myers Squibb | Hepatitis C Virus Genotype 4 Infection | December 2014 |
Phase 2 |
NCT01628692 | Bristol-Myers Squibb|Janssen Research & Development, LLC | Hepatitis C Virus | July 2012 |
Phase 2 |
NCT03186313 | Egyptian Liver Hospital|Wadi El Nil Hospital | Hepatitis C | September 2016 |
Phase 3 |
NCT03063723 | Third Affiliated Hospital, Sun Yat-Sen University | Chronic Hepatitis C (Disorder) | January 1, 2016 |
|
NCT00983957 | Bristol-Myers Squibb | Chronic Hepatitis C | October 2009 |
Phase 1 |
NCT01725542 | French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Bristol-Myers Squibb | HCV-HIV Co-Infection | December 2012 |
Phase 2 |
NCT02282709 | Foundation for Liver Research | Chronic Hepatitis C | February 2014 |
Phase 3 |
NCT02032888 | Bristol-Myers Squibb | Hepatitis C | February 2014 |
Phase 3 |
NCT03247296 | MTI University | Hepatitis C | February 28, 2017 |
|
NCT01389323 | Bristol-Myers Squibb | Hepatitis C | September 2011 |
Phase 3 |
NCT02556086 | Bristol-Myers Squibb | Hepatitis C | December 2015 |
Phase 2 |
NCT01741545 | Bristol-Myers Squibb | Hepatitis C Virus | March 31, 2013 |
Phase 3 |
NCT01866930 | Bristol-Myers Squibb | Chronic Hepatitis C Infection | July 11, 2013 |
Phase 3 |
NCT02268864 | Janssen-Cilag International NV | Hepatitis C, Chronic | January 2015 |
Phase 2 |
NCT01797848 | Bristol-Myers Squibb | Hepatitis C | June 2014 |
Phase 3 |
NCT03166280 | Eman Sayed Hassan Abd Allah|Assiut University | Hepatitis C | June 2017 |
|
NCT02159352 | Bristol-Myers Squibb | Hepatitis C | June 2014 |
Phase 1 |
NCT01125189 | Bristol-Myers Squibb | Hepatitis C Virus | July 2010 |
Phase 2 |
NCT03748745 | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Drug Interactions | November 19, 2018 |
Phase 1 |
NCT01012895 | Bristol-Myers Squibb | Chronic Hepatitis C | December 2009 |
Phase 2 |
NCT02565888 | Radboud University | Hepatitis C|HIV | November 2015 |
Phase 1 |
NCT02555943 | Humanity and Health Research Centre|Beijing 302 Hospital|Nanfang Hospital of Southern Medical University | Chronic Hepatitis C Infection|HBV Coinfection|Hepatitis B Reactivation | February 2015 |
Phase 2|Phase 3 |
NCT02304159 | Tarek I. Hassanein, M.D., FACP, FAG, AGAF|Southern California Research Center | Hepatitis C|Cirrhosis | January 2015 |
Phase 4 |
NCT02580474 | Myeong Jun Song|Bristol-Myers Squibb|Soonchunhyang University Hospital|Dankook University|Chungnam National University Hospital|Konyang University Hospital|Eulji University Hospital|Saint Vincent´s Hospital, Korea|Konkuk University Hospital|Cheongju St. Mary´s Hospital, Cheongju, Korea|Severance Hospital|Korea University Guro Hospital|Eulji General Hospital|The Catholic University of Korea | Hepatitis C | February 2016 |
Phase 4 |
NCT02104843 | Bristol-Myers Squibb | Hepatitis C | April 2014 |
Phase 1 |
NCT01428063 | Bristol-Myers Squibb | Hepatitis C Virus Infection | September 2011 |
Phase 2 |
NCT02123654 | Bristol-Myers Squibb | Hepatitis C Virus Infection | April 2014 |
Phase 3 |
NCT02565862 | Radboud University | Hepatitis C|Diabetes Mellitus|Insulin Resistance | January 2016 |
Phase 1 |
NCT04211844 | Ain Shams University | Chronic Hepatitis C | October 1, 2019 |
|
NCT00874770 | Bristol-Myers Squibb | Hepatitis C Infection | June 2009 |
Phase 2 |
NCT03883698 | Sanjay Gandhi Postgraduate Institute of Medical Sciences | Kidney Failure, Chronic|Hepatitis C | March 15, 2019 |
Phase 3 |
NCT01448044 | Bristol-Myers Squibb | Hepatitis C | December 2011 |
Phase 3 |
NCT01359644 | Bristol-Myers Squibb|Pharmasset | Chronic Hepatitis C | June 2011 |
Phase 2 |
NCT01842451 | Vertex Pharmaceuticals Incorporated | Chronic Hepatitis C|CHC|HCV|Hepatitis C | June 2013 |
Phase 2 |
NCT02762448 | Tainan Municipal Hospital | Hepatitis c | July 2016 |
|
NCT02473211 | Humanity and Health Research Centre|Beijing 302 Hospital | Chronic Hepatitis C Infection | January 2015 |
Phase 2|Phase 3 |
NCT01455090 | Bristol-Myers Squibb | Chronic Hepatitis C | November 30, 2011 |
Phase 2 |
NCT03490097 | Ain Shams University | Chronic Hepatitis c|Metabolic Syndrome | December 1, 2017 |
Phase 2|Phase 3 |
NCT01170962 | Bristol-Myers Squibb | Hepatitis C Virus | August 2010 |
Phase 2 |
NCT02333292 | Valme University Hospital|Hospital del SAS de Jerez|Hospital General Universitario Elche|Hospital La Línea de la Concepción|Complexo Hospitalario Universitario de A Coruña|Hospital de Figueres|Hospital Universitario Puerto Real|Hospital Universitario Virgen de la Victoria|Hospital Universitario de Canarias|Hospital General Universitario de Alicante|Hospital Universitario Araba|Hospital Royo Vilanova|Hospital Universitario de Burgos|Complejo Hospitalario Universitario de Huelva|Hospital Universitario Reina Sofia de Cordoba|Hospital Universitario Virgen Macarena|Complexo Hospitalario Universitario de Vigo|Clinica Universidad de Navarra, Universidad de Navarra|Hospital Clinico Universitario San Cecilio|Hospital Universitario La Fe|Hospital General Universitario de Valencia|Hospital Universitario Infanta Leonor|Hospital Universitario de Gran Canaria|Hospital General Universitario Santa Lucía|Centro Penitenciario Alicante 1|Hospital Regional Universitario Carlos Haya|Hospital Virgen de la Luz|Hospital General Universitario de Castellón|Hospital Parc Taulí, Sabadell | Chronic Hepatitis C Infection | December 2014 |
|
NCT03200184 | Tehran University of Medical Sciences | Hepatitis C | September 1, 2016 |
Phase 4 |
NCT03188276 | Third Affiliated Hospital, Sun Yat-Sen University | Chronic Hepatitis C | February 1, 2016 |
Early Phase 1 |
NCT01830205 | Bristol-Myers Squibb | Hepatitis C | September 2012 |
Phase 1 |
Proposal 18 Quality Consistency Evaluation projects which have approved 4, and 6 projects are under approving.
Advanced international quality management system has laid solid foundation for sales.
Quality supervision runs through the whole life cycle of the product to ensure the quality and therapeutic effect.
Professional Regulatory Affairs team supports the quality demands during the application and registration.